Clinical Trials Logo

Communicable Diseases clinical trials

View clinical trials related to Communicable Diseases.

Filter by:

NCT ID: NCT05252468 Completed - COVID-19 Clinical Trials

COVID-19 Prevention Trial: Effect of Prophylactic Use of TAFFIX™ on Infection Rate by SARS-CoV-2 Virus (COVID-19).

Start date: May 19, 2021
Phase: N/A
Study type: Interventional

TAFFIX is a nasal powder spray that immediately creates a protective acidic barrier on the nasal mucosa against infection by inhaled viruses. The protective barrier lasts 5 hours. TAFFIX is approved as a medical device in Israel, intended for use to block inhaled viruses within the nasal cavity. In Europe, it is registered as a medical device indicated for use as a protective mechanical barrier against allergens and viruses (e.g., SARS-CoV-2) within the nasal cavity. TAFFIX is used as additional safety mean together with masks, hygiene, and social distancing. The study rationale is to evaluate whether daily use of TaffiX™ as prophylaxis will reduce the rate of SARS- CoV-2 infection and other upper respiratory infections, compared to the placebo control rate.

NCT ID: NCT05251584 Recruiting - Clinical trials for Peritoneal Dialysis-related Infection

Effects of Topical Gentamicin on the Prevention of Peritoneal Dialysis Related Infection

Start date: December 1, 2021
Phase: N/A
Study type: Interventional

Peritoneal dialysis-related infection is a complication that leads to peritoneal dialysis catheter removal or patient death. The present study aimed to investigate peritoneal dialysis-related infection, causative pathogens resulting in topical 2% mupirocin ointments period compare with 0.1% gentamicin cream period. Rate of catheter removal, time to first peritoneal dialysis-related infection after apply gentamicin cream.

NCT ID: NCT05250050 Recruiting - Clinical trials for Helicobacter Pylori Infection

Susceptibility-Guided Therapy for Helicobacter Pylori Infection Treatment

Start date: March 25, 2022
Phase: Phase 4
Study type: Interventional

This multicenter randomized controlled clinical trial was conducted to compare the eradication efficacy and health economic benefits of individualized regimens based on HP drug resistance mutation gene detection (multiple PCR method), individualized regimens based on HP traditional drug sensitivity testing (E-test method) and empirical regimens in the Helicobacter pylori treatment.

NCT ID: NCT05248490 Completed - Clinical trials for Bone and Joint Infection

Impact of Pharmaceutical Interviews Regarding the Management of Adverse Effects Related to the Antibiotic Therapy Used to Treat Osteoarticular Infections During Return Home

EFIRAD
Start date: March 22, 2022
Phase: N/A
Study type: Interventional

The primary objective is to evaluate the impact of Pharmaceutical Interviews in the patient self-management of non-severe side effects caused by antibiotics prescribed for the treatment of osteoarticular infections when the patient returns home.

NCT ID: NCT05247112 Recruiting - Clinical trials for Helicobacter Pylori Infection

Prevalence and Trends of Antimicrobial Resistance of Helicobacter Pylori in Korea

Start date: July 1, 2003
Phase:
Study type: Observational

To assess antimicrobial resistance rates and minimal inhibitory concentrations in H. pylori isolated from patients with upper gastrointestinal disease with long-term period.

NCT ID: NCT05244967 Recruiting - Clinical trials for Sexually Transmitted Infection

Epidemiology of Sexually Transmitted Infections and Its iMpAcT on fEmale Infertility

ESTIMATE
Start date: November 11, 2020
Phase:
Study type: Observational

A longitudinal study to investigate the prevalence of sexually transmitted infections among young women and determine the role of the female genital tract microbiome in fertility

NCT ID: NCT05244655 Completed - Postoperative Pain Clinical Trials

Early Postoperative Pain and 30-day Complications Following Major Abdominal Surgery: an Observational Study

Start date: December 1, 2021
Phase:
Study type: Observational [Patient Registry]

In this retrospective cohort study, we assess the relationship between the intensity of early postoperative pain and the risk of infectious- and non-infectious complications within 30 days after major abdominal surgery.

NCT ID: NCT05244356 Completed - COVID-19 Clinical Trials

Health Communication to Influence COVID-19 Vaccination Intent and Message Propagation

CONVINCE
Start date: April 29, 2021
Phase: N/A
Study type: Interventional

This is a randomised controlled experiment in the form of a web based survey study which randomly exposes participants to different forms of public health messages, after which participants will be assessed on their intent to take up the COVID-19 vaccine, recommend the vaccine, and also willingness to propagate the exposed message.

NCT ID: NCT05243381 Recruiting - HIV Infections Clinical Trials

Inflammation, NK Cells, Antisense Protein and Exosomes, and Correlation With Immune Response During HIV Infection

INKASE
Start date: April 22, 2022
Phase: N/A
Study type: Interventional

More than 90% of HIV-infected patients on antiretroviral therapy have an undetectable viral load. However, approximately 15% of these individuals do not sufficiently restore their TCD4 lymphocytes and have an unfavorable CD4/CD8 ratio despite good adherence and an undetectable viral load. Factors associated with immunovirological discordance include low CD4 cell counts prior to antiretroviral therapy, low CD4/CD8 ratios and positive cytomegalovirus (CMV) serology. These patients are at risk of significant non-AIDS events and mortality. The anti-sense protein (ASP) is synthesized from the anti-sense strand of HIV-1. A cytotoxic anti-ASP response of CD8 T lymphocytes and anti-ASP antibodies have been demonstrated in infected patients. The conservation of the ASP gene in HIV-1, the virus responsible for the pandemic, suggests that its maintenance confers an advantage to the virus. ASP induces an inflammatory phenotype in surrounding cells. ASP can be externalized by the cell through its interaction with its cellular partner Bat-3. Once externalized in soluble or exosomal form, Bat-3 has the ability to regulate NK cell activity. During HIV infection, NK functions are disrupted, including those related to the expression of the Bat-3 receptor, NKp30. In patients, the inflammatory phenomenon is strongly associated with chronic HIV-1 infection. The efficacy of antiviral treatments does not allow a complete normalization of either the immune system function or the inflammatory status of the patient. The observed effect of ASP on inflammation raises the question of the involvement of ASP in the maintenance of a chronic inflammatory state in patients under treatment. Increased inflammation has also been associated in HIV-infected patients with elevated plasma exosome levels. In patients undergoing treatment, chronic inflammation remains a major problem and an important source of comorbidities (cardiovascular in particular) and probably contributes to the immunovirological non-response in immunodiscordant HIV-infected patients. It is hypothesized that ASP bound to its cellular partner Bat-3 in exosomes would disrupt the cytotoxic activity of NK cells, sustain inflammation and have a deleterious effect on immune reconstitution.

NCT ID: NCT05242172 Active, not recruiting - Clinical trials for Corona Virus Infection

THE RELATIONSHIP OF CRP/ALBUMIN RATIO LEVEL AND PROGNOSIS IN PREGNANT COVID-19 PATIENTS

Start date: January 15, 2022
Phase:
Study type: Observational

The CRP/albumin ratio (CAR) is a recently defined parameter which represents the ratio of a positive acute phase reactant to a negative acute phase reactant. Recent studies have shown that the CRP/albumin ratio is a biomarker with prognostic value for various inflammatory disorders and serious diseases. With this study it is aimed to investigate the effect of CRP/albumin ratio in predicting the severity and prognosis of the disease in pregnant patients with more severe Covid-19 infection.